In 2023, painkiller use continued to shape public health discussions amid rising opioid concerns and expanded access to alternative therapies. This year highlighted how different classes of analgesics, from NSAIDs to novel nerve blocks, compete to manage both acute and chronic pain.
Regulatory updates, real-world effectiveness data, and patient preferences drove shifts in prescribing, making it essential for clinicians and consumers to understand current options, risks, and value. The following sections organize key dimensions of painkiller landscape in 2023 for quick reference and deeper exploration.
| Agent | Type | Typical Use | Key Safety Flags |
|---|---|---|---|
| Ibuprofen | NSAID | Mild to moderate pain, inflammation | GI irritation, renal risk |
| Acetaminophen | Analgesic/antipyretic | Mild pain, fever | Hepatotoxicity above dose limit |
| Oxycodone with acetaminophen | Opioid | Moderate to severe postoperative pain | Respiratory depression, misuse potential |
| Gabapentin | Adjuvant analgesic | Neuropathic pain, adjunct for seizures | Sedation, dizziness, misuse trends |
| Lidocaine patches | Local anesthetic | Localized neuropathic pain | Skin reactions, systemic absorption risk |
Prescribing Patterns and Regulatory Shifts in 2023
Opioid Prescribing Trends
During 2023, health authorities reported cautious declines in opioid prescriptions in certain high-income regions, driven by stricter monitoring programs and greater use of non-opioid protocols. Clinicians faced renewed requirements for prescription drug monitoring program checks and co-prescription of naloxone in many jurisdictions.
Guidelines for Non-Opioid Analgesics
Professional societies emphasized multimodal pain control, prioritizing NSAIDs, acetaminophen, and regional anesthesia where appropriate. For chronic conditions, guidelines underscored structured trials of gabapentinoids, SNRIs, and topical agents before considering opioids, reflecting both efficacy and safety considerations.
Safety, Side Effects, and Contraindications
Common Adverse Events
NSAIDs raised concerns for gastrointestinal bleeding and cardiovascular events, prompting clinicians to assess individual risk and use gastroprotection when indicated. Opioids carried risks of constipation, nausea, dizziness, and dependence, highlighting the need for clear risk mitigation plans and tapering strategies.
Special Population Considerations
Pregnant individuals, older adults, and patients with liver or kidney impairment required tailored dosing and closer monitoring. In 2023, advisories on acetaminophen maximum daily doses and NSAID avoidance in advanced chronic kidney disease reinforced the role of personalized risk assessment.
Patient Access, Affordability, and Value
Generics and Pricing Landscape
Many commonly used painkillers remained low-cost generics, yet newer agents and extended-release formulations retained higher price points, affecting adherence and formulary decisions. Payers and providers increasingly referenced value assessments that balanced acquisition cost, effectiveness, and safety profile.
Formulary and Reimbursement Trends
Formularies in 2023 showed narrower step-therapy requirements for some non-opioid options and increased utilization management for certain neuromodulators. This aimed to control spend while ensuring timely access for patients with documented medical necessity.
Alternative and Adjunctive Pain Management
Nonsystem and Nonpharmacologic Options
Growing interest in physical therapy, acupuncture, cognitive behavioral therapy, and neuromodulation devices offered patients additional tools beyond pills. Clinicians integrated these approaches into pain management plans where evidence supported meaningful benefit and tolerability.
Digital Health and Remote Monitoring
Telehealth platforms and digital pain diaries enabled more nuanced tracking of symptoms, side effects, and functional outcomes in 2023. These tools supported more timely adjustments to therapy and empowered patients to engage actively in their care.
Optimizing Painkiller Use in 2023
- Prioritize non-opioid, nonpharmacologic options when clinically appropriate.
- Apply structured risk assessment before initiating or continuing opioids.
- Monitor renal, hepatic, and cardiovascular parameters regularly.
- Leverage digital tools and care coordination to track response and adjust therapy.
- Align prescribing with current guidelines and formulary policies to ensure safe, value-based care.
FAQ
Reader questions
Are NSAIDs safe for long-term use to manage chronic pain in older adults?
Long-term NSAID use in older adults requires careful risk evaluation due to higher rates of gastrointestinal, renal, and cardiovascular adverse effects. Clinicians often recommend using the lowest effective dose, adding gastroprotection when appropriate, and regularly reviewing medication appropriateness with consideration of non-drug strategies.
Can gabapentin be stopped abruptly without withdrawal symptoms?
Abrupt discontinuation of gabapentin may lead to withdrawal symptoms such as anxiety, insomnia, nausea, and sweating. A gradual taper under medical supervision is generally recommended to minimize these effects, particularly after prolonged use or higher doses.
How does pregnancy affect painkiller choices and dosing adjustments?
During pregnancy, clinicians prefer non-pharmacologic and low-risk options when possible, reserving pharmacologic therapy for clear medical need. Many standard doses remain appropriate, but altered pharmacokinetics and fetal considerations often require individualized choices and closer monitoring.
What signs indicate that an opioid dose should be reviewed or reduced in a chronic pain patient?
Signs suggesting a review include dose escalation without clear functional benefit, side effects such as excessive sedation or constipation, concurrent high-risk medications like benzodiazepines, and challenges with tapering when goals are no longer met.